MCID: OLG002
MIFTS: 66

Oligodendroglioma

Categories: Bone diseases, Cancer diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Oligodendroglioma

MalaCards integrated aliases for Oligodendroglioma:

Name: Oligodendroglioma 12 20 58 29 54 6 44 15 17 70
Oligodendroglial Neoplasm 12 70
Oligodendroglial Tumor 12 58
Well Differentiated Oligodendroglioma 70
Oligodendroglial Tumors 54

Characteristics:

Orphanet epidemiological data:

58
oligodendroglioma
Inheritance: Not applicable; Age of onset: All ages;
oligodendroglial tumor
Inheritance: Multigenic/multifactorial,Not applicable; Age of onset: Adult;

Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:3181
MeSH 44 D009837
NCIt 50 C3288
SNOMED-CT 67 443936004
ICD10 via Orphanet 33 C71.9
UMLS via Orphanet 71 C0028945
UMLS 70 C0028945 C0751396 C1335110

Summaries for Oligodendroglioma

GARD : 20 Oligodendrogliomas are brain tumors arising from oligodendrocytes, a type of cell that makes up the supportive (glial) tissue of the brain. They can be low-grade (grade II) or high-grade (grade III, also called anaplastic). While they can be found anywhere within the cerebral hemisphere, they are most common in the frontal and temporal lobes. They are generally soft, grayish-pink tumors that often contain mineral deposits (calcifications), areas of hemorrhage, and/or cysts. They tend to grow slowly and may be present for many years before they are diagnosed. Common symptoms include seizures, headaches and changes in personality. Other symptoms vary by the size and location of the tumor. The exact cause of opigodendrogliomas is unknown. Some appear to have a chromosome abnormality involving loss of chromosomes 1p and 19q. Treatment generally involves surgical removal of the tumor followed by radiation therapy and/or chemotherapy. Recurrent tumors may need additional surgery, radiation and chemotherapy.

MalaCards based summary : Oligodendroglioma, also known as oligodendroglial neoplasm, is related to oligoastrocytoma and adult oligodendroglioma. An important gene associated with Oligodendroglioma is CIC (Capicua Transcriptional Repressor), and among its related pathways/superpathways are Pathways in cancer and Gastric cancer. The drugs Trametinib and Dabrafenib have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and eye, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Wikipedia : 73 Oligodendrogliomas are a type of glioma that are believed to originate from the oligodendrocytes of the... more...

Related Diseases for Oligodendroglioma

Diseases in the Oligodendroglioma family:

Adult Oligodendroglioma

Diseases related to Oligodendroglioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 456)
# Related Disease Score Top Affiliating Genes
1 oligoastrocytoma 32.8 MGMT IDH2 GFAP
2 adult oligodendroglioma 32.7 OLIG2 IDH2 IDH1 FUBP1
3 anaplastic oligodendroglioma 32.7 POT1 OLIG2 OLIG1 MGMT IDH2 CIC
4 childhood oligodendroglioma 32.5 OLIG2 MGMT IDH2 IDH1 FUBP1 ATRX
5 glial tumor 32.4 PTEN OLIG2 EGFR
6 spinal cord oligodendroglioma 32.3 TP53 SYP MGMT IDH1 GFAP EGFR
7 mixed oligodendroglioma-astrocytoma 31.9 TP53 PTEN MGMT IDH2 IDH1 CDKN2B
8 central neurocytoma 31.3 SYP OLIG2 GFAP
9 low grade glioma 31.2 TP73 MGMT IDH2 IDH1
10 malignant astrocytoma 31.2 TP53 PTEN OLIG2 MGMT IDH2 IDH1
11 dysembryoplastic neuroepithelial tumor 31.2 SYP OLIG2 IDH1 GFAP
12 benign ependymoma 31.1 SYP PTEN IDH1 GFAP
13 cellular ependymoma 31.1 SYP MGMT GFAP EGFR
14 glioma 31.0 TP53 PTEN POT1 IDH2 IDH1 EGFR
15 clear cell ependymoma 31.0 SYP OLIG2 IDH1 GFAP
16 intracranial meningioma 30.9 MGMT CDKN2A
17 ganglioglioma 30.9 TP53 SYP GFAP
18 extraventricular neurocytoma 30.9 SYP IDH1 GFAP
19 glioblastoma 30.9 TP53 PTEN MGMT IDH2 IDH1 GFAP
20 hydrocephalus 30.9 TP53 SYP PTEN MBP GFAP
21 teratoma 30.9 TP53 SYP PTEN GFAP CDKN2A
22 gangliocytoma 30.8 SYP PTEN GFAP
23 angiocentric glioma 30.8 SYP IDH1 GFAP
24 cystic teratoma 30.7 TP53 SYP PTEN GFAP CDKN2A
25 astroblastoma 30.6 SYP IDH1 GFAP
26 mixed glioma 30.6 TP53 PTEN OLIG2 MGMT IDH2 IDH1
27 pilocytic astrocytoma 30.6 TP53 SYP PTEN OLIG2 MGMT IDH1
28 high grade glioma 30.6 TP53 PTEN MGMT IDH2 IDH1 GFAP
29 gliomatosis cerebri 30.5 TP53 SYP PTEN IDH1 GFAP EGFR
30 enchondroma 30.5 IDH2 IDH1
31 cerebral neuroblastoma 30.4 SYP GFAP
32 pleomorphic xanthoastrocytoma 30.4 TP53 SYP MGMT IDH1 GFAP ATRX
33 obstructive hydrocephalus 30.4 SYP OLIG2 GFAP
34 diffuse astrocytoma 30.4 TP53 OLIG2 MGMT IDH2 IDH1 GFAP
35 brain glioma 30.4 TP53 MGMT IDH2 IDH1 GFAP FUBP1
36 pilomyxoid astrocytoma 30.4 SYP IDH1 GFAP ATRX
37 diffuse midline glioma, h3 k27m-mutant 30.4 TP53 OLIG2 MGMT IDH1 ATRX
38 meningioma, familial 30.3 TP73 TP53 SYP PTEN GFAP EGFR
39 gliosarcoma 30.2 TP53 PTEN OLIG2 MGMT IDH2 IDH1
40 cauda equina syndrome 30.2 SYP GFAP
41 low-grade astrocytoma 30.2 TP53 IDH1 CDKN2B CDKN2A
42 brain cancer 30.1 TP73 TP53 SYP PTEN OLIG2 OLIG1
43 neuroblastoma 30.1 TP73 TP53 SYP PTEN EGFR CDKN2A
44 adenoma 30.1 TP53 SYP MGMT CDKN2A
45 central nervous system lymphoma 30.1 TP53 MGMT CDKN2A
46 tuberous sclerosis 30.1 TP53 SYP PTEN GFAP
47 adult astrocytic tumour 30.1 TP53 PTEN IDH2 IDH1 ATRX
48 neurofibromatosis, type i 30.1 TP53 PTEN EGFR CDKN2A
49 gemistocytic astrocytoma 30.0 TP53 PTEN IDH2 IDH1 GFAP ATRX
50 leukemia, acute lymphoblastic 30.0 TP73 TP53 PTEN CDKN2C CDKN2B CDKN2A

Graphical network of the top 20 diseases related to Oligodendroglioma:



Diseases related to Oligodendroglioma

Symptoms & Phenotypes for Oligodendroglioma

GenomeRNAi Phenotypes related to Oligodendroglioma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.55 CDKN2A CIC GMNN POT1 PTEN TP73
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.55 CDKN2A CIC GMNN POT1 PTEN TP53
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-3 9.55 CIC POT1 TP53 TP73

MGI Mouse Phenotypes related to Oligodendroglioma:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 mortality/aging MP:0010768 10.36 ATRX CDKN2A CDKN2B CDKN2C CIC EGFR
2 behavior/neurological MP:0005386 10.34 ATRX CDKN2A CDKN2C CIC GFAP GMNN
3 cellular MP:0005384 10.32 ATRX CDKN2A CDKN2B CDKN2C EGFR GFAP
4 growth/size/body region MP:0005378 10.3 ATRX CDKN2A CDKN2C CIC EGFR FUBP1
5 nervous system MP:0003631 10.22 ATRX CDKN2A CDKN2C CIC EGFR FUBP1
6 immune system MP:0005387 10.21 CDKN2A CDKN2B CDKN2C EGFR FUBP1 GFAP
7 endocrine/exocrine gland MP:0005379 10.18 CDKN2A CDKN2B CDKN2C EGFR FUBP1 GMNN
8 embryo MP:0005380 10.15 ATRX CDKN2A EGFR FUBP1 GMNN POT1
9 neoplasm MP:0002006 10.07 CDKN2A CDKN2B CDKN2C EGFR IDH2 MGMT
10 reproductive system MP:0005389 9.85 ATRX CDKN2A CDKN2B CDKN2C EGFR GMNN
11 no phenotypic analysis MP:0003012 9.8 CDKN2A CDKN2B EGFR MGMT OLIG2 POT1
12 respiratory system MP:0005388 9.7 CDKN2A CDKN2C CIC EGFR FUBP1 IDH1
13 vision/eye MP:0005391 9.32 ATRX CDKN2A EGFR GFAP GMNN MBP

Drugs & Therapeutics for Oligodendroglioma

Drugs for Oligodendroglioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 173)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Trametinib Approved Phase 4 871700-17-3 11707110
2
Dabrafenib Approved, Investigational Phase 4 1195765-45-7 44462760 44516822
3
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
4
Procarbazine Approved, Investigational Phase 3 671-16-9 4915
5
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
6
carbamide peroxide Approved Phase 2 124-43-6
7
Topotecan Approved, Investigational Phase 2 123948-87-8, 119413-54-6 60700
8
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
9
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
10
Romidepsin Approved, Investigational Phase 1, Phase 2 128517-07-7 5352062
11
Gefitinib Approved, Investigational Phase 1, Phase 2 184475-35-2 123631
12
Streptozocin Approved, Investigational Phase 2 18883-66-4 29327
13
Mercaptopurine Approved Phase 2 50-44-2 667490
14
Nintedanib Approved Phase 2 656247-17-5 56843413
15
Etoposide Approved Phase 1, Phase 2 33419-42-0 36462
16
Melphalan Approved Phase 1, Phase 2 148-82-3 4053 460612
17
Mechlorethamine Approved, Investigational Phase 1, Phase 2 51-75-2 4033
18
Mannitol Approved, Investigational Phase 1, Phase 2 69-65-8 6251 453
19
Carboplatin Approved Phase 1, Phase 2 41575-94-4 10339178 498142 38904
20
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
21
Cetuximab Approved Phase 1, Phase 2 205923-56-4 56842117 2333
22
Busulfan Approved, Investigational Phase 2 55-98-1 2478
23
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
24
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
25
Panobinostat Approved, Investigational Phase 2 404950-80-7 6918837
26
Bevacizumab Approved, Investigational Phase 1, Phase 2 216974-75-3
27
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 6436030 5284616
28
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
29
Lopinavir Approved Phase 2 192725-17-0 92727
30
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
31
Phenylalanine Approved, Investigational, Nutraceutical Phase 1, Phase 2 63-91-2 6140
32
tipifarnib Investigational Phase 2 192185-72-1 159324
33
Etirinotecan pegol Investigational Phase 2 848779-32-8
34
Trebananib Investigational Phase 2 894356-79-7
35
Imetelstat Investigational Phase 2 868169-64-6
36 Imatinib Mesylate Phase 1, Phase 2 220127-57-1 123596
37 Muromonab-CD3 Phase 2
38 Fluorodeoxyglucose F18 Phase 2
39 Deoxyglucose Phase 2
40 Bendamustine Hydrochloride Phase 2
41 Tubulin Modulators Phase 2
42 Antimitotic Agents Phase 2
43 Etoposide phosphate Phase 1, Phase 2
44 sodium thiosulfate Phase 1, Phase 2
45 diuretics Phase 1, Phase 2
46 Keratolytic Agents Phase 1, Phase 2
47 Antitubercular Agents Phase 1, Phase 2
48 Nitrogen Mustard Compounds Phase 1, Phase 2
49 Podophyllotoxin Phase 1, Phase 2 518-28-5
50
Liposomal doxorubicin Phase 2 31703

Interventional clinical trials:

(show top 50) (show all 183)
# Name Status NCT ID Phase Drugs
1 An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib) Recruiting NCT03975829 Phase 4 dabrafenib;trametinib
2 Phase 3 Study of Carmustine Sustained Release Implant (CASANT) to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
3 PHASE III STUDY OF ADJUVANT PROCARBAZINE, CCNU AND VINCRISTINE CHEMOTHERAPY IN PATIENTS WITH HIGHLY ANAPLASTIC OLIGODENDROGLIOMA Completed NCT00002840 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
4 Phase III Intergroup Randomized Comparison of Radiation Alone vs. Pre-Radiation Chemotherapy for Pure and Mixed Anaplastic Oligodendrogliomas Completed NCT00002569 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
5 NOA-04 Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide Completed NCT00717210 Phase 3 Temozolomide
6 A Randomized Trial of Delayed Radiotherapy in Patients With Newly Diagnosed 1p/19q Codeleted Anaplastic Oligodendroglial Tumors: the POLCA Trial. Recruiting NCT02444000 Phase 3 PCV chemotherapy alone;Radiotherapy+PCV chemotherapy
7 Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma Recruiting NCT01649830 Phase 3 Temozolomide
8 A Randomized Trial of Delayed Radiotherapy in Patients 1p/19q Codeleted Low-grade Oligodendrogliomas Requiring a Treatment Other Than Surgery Not yet recruiting NCT04702581 Phase 3 PCV chemotherapy;Radiotherapy and PCV chemotherapy
9 Treatment Strategy for Low-grade Gliomas Terminated NCT00897377 Phase 3 Temozolomide
10 A Phase II/III Randomized, Open-Label Study of Toca 511, A Retroviral Replicating Vector, Combined With Toca FC With Temozolomide and Radiation Followed by Adjuvant Temozolomide and Toca FC Compared to Temozolomide and Radiation Followed by Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma Withdrawn NCT04105374 Phase 2, Phase 3 Extended Release Flucytosine;Temozolomide
11 A Phase 2 Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain Unknown status NCT01403311 Phase 2 5-Aminolevuline Acid
12 A Phase 1/2 Multi-Center, Safety and Efficacy Study Evaluating Intravenously Administered 131I-TM601 in Patients With Progressive and/or Recurrent Malignant Glioma Unknown status NCT00683761 Phase 1, Phase 2 131I-TM601
13 Phase I/II Clinical Trial of the Safety, Tolerability, and Anti-tumor Efficacy of the IGF-1R Inhibitor, AXL1717 (Picropodophyllin), in the Treatment of Recurrent Malignant Astrocytomas Unknown status NCT01721577 Phase 1, Phase 2 AXL1717
14 A Prospective Cohort to Study the Effect of Postoperative Upfront Temozolomide Chemotherapy on IDH Mutational Low Grade Gliomas in Eloquent Areas Unknown status NCT02209428 Phase 2 Temozolomide
15 A Phase II Study of Prolonged Daily Temozolomide for Low-Grade Glioma Completed NCT00165360 Phase 2 Temozolomide
16 Phase II Pilot, Prospective, Open Label, Multicenter CT, to Evaluate the Safety and Efficacy of Palbociclib (PD0332991), a Cyclin-dependent Kinase 4 and 6 (CDK4 and CDK6) Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved Completed NCT02530320 Phase 2 Palbociclib
17 Second Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors After PCV-Chemotherapy Completed NCT00003304 Phase 2 temozolomide
18 First Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors, a Phase II Trial Completed NCT00003731 Phase 2 temozolomide
19 Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma Completed NCT00049127 Phase 1, Phase 2 Imatinib Mesylate
20 Primary Chemotherapy by BCNU-TMZ Combination in Newly Diagnosed Anaplastic Oligodendrocytic Tumors: Phase II Trial With Translational Molecular Analysis Completed NCT04755023 Phase 2 Bis-Chloroethyl-Nitroso-Urea (BCNU) withTemozolomide
21 The Efficacy and Safety of Temozolomide in Patients With Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: a Multicenter, Single-arm, Phase II Trial Completed NCT01847235 Phase 2 Temozolomide
22 Phase II Trial of Continuous Dose Temozolomide in Patients With Newly Diagnosed Pure and Mixed Anaplastic Oligodendroglioma Completed NCT00400816 Phase 2 temozolomide
23 A Phase II Study of Topotecan in Patients With Anaplastic Oligodendroglioma or Anaplastic Mixed Oligoastrocytoma Completed NCT00003372 Phase 2 topotecan hydrochloride
24 Phase II Treatment of Adults With Newly Diagnosed, Progressive or Recurrent Primary Malignant Anaplastic Oligodendroglioma With Temodal Completed NCT00003465 Phase 2 temozolomide
25 Phase II Trial of Continuous Dose Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma Completed NCT00362570 Phase 2 Temozolomide
26 A Phase II Trial of Intensive Chemotherapy and Autotransplantation for Patients With Newly Diagnosed Anaplastic Oligodendroglioma Completed NCT00003101 Phase 2 busulfan;lomustine;procarbazine hydrochloride;thiotepa;vincristine sulfate
27 A Phase II Trial Of Pre-Irradiation And Concurrent Temozolomide In Patients With Newly Diagnosed Anaplastic Oligodendrogliomas And Mixed Anaplastic Oligoastrocytomas Completed NCT00033280 Phase 2 temozolomide
28 CAMP 013:- Tandem Thiotepa Regimen For Selected Malignant Gliomas:1) Primary Or Recurrent Glioblastoma Multiforme (GBM); and 2) Recurrent Anaplastic Astrocytomas (AA), Oligodendrogliomas (O), Oligoastrocytomas (OA), Ependymomas And Primitive Neuroectodermal Tumors (PNET) That Have Either Progressed After Primary Therapy Or Are Refractory To Standard Chemotherapy Completed NCT00008008 Phase 2 cyclophosphamide;thiotepa
29 The Temozolomide RESCUE Study: A Phase II Trial of Continuous (28/28) Dose-intense Temozolomide (CDIT) Chemotherapy After Progression on Conventional 5/28 Day Temozolomide in Patients With Recurrent Malignant Glioma Completed NCT00392171 Phase 2 Temozolomide
30 Phase I/II Study of OSI-774 (Erlotinib) and CCI-779 (Temsirolimus) in Patients With Recurrent Malignant Glioma Completed NCT00112736 Phase 1, Phase 2 erlotinib;temsirolimus
31 Phase II Trial of Irinotecan in Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
32 Immunotherapy for Malignant Glioma - Phase II Trial of Autologous Cancer Antigen Specific Immunotherapy Completed NCT00004024 Phase 2
33 Molecular Biology and Phase II Study of Lapatinib (GW572016) in Pediatric Patients With Recurrent or Refractory Medulloblastoma, Malignant Glioma or Ependymoma Completed NCT00095940 Phase 1, Phase 2 lapatinib ditosylate
34 A Phase I/II Trial of OSI-774 in Patients With Recurrent Malignant Gliomas and Malignant Gliomas Post Radiation Therapy Completed NCT00045110 Phase 1, Phase 2 erlotinib hydrochloride
35 A Phase II Study of Sunitinib (NSC# 736511) in Recurrent, Refractory or Progressive High Grade Glioma and Ependymoma Tumors in Pediatric and Young Adult Patients Completed NCT01462695 Phase 2 Sunitinib Malate
36 A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage Completed NCT00492089 Phase 2 bevacizumab;placebo
37 Phase II Study of Bevacizumab Plus Irinotecan (Camptosar™) in Children With Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas, Ependymomas and Low Grade Gliomas Completed NCT00381797 Phase 2 Irinotecan Hydrochloride
38 Phase II Single Arm Trial of VEGF Trap in Patients With Recurrent Temozolomide-Resistant Malignant Gliomas Completed NCT00369590 Phase 2
39 A Phase I-II Trial of Depsipeptide in Patients With Recurrent High-Grade Gliomas Completed NCT00085540 Phase 1, Phase 2 depsipeptide
40 A Phase II Study of R115777 (Zarnestra) (NSC # 702818, IND# 58,359) in Children With Recurrent or Progressive: High Grade Glioma, Medulloblastoma/PNET or Brainstem Glioma Completed NCT00070525 Phase 2 tipifarnib
41 Phase I/II Trial of Gefitinib and Radiation in Pediatric Patients Newly Diagnosed With Brain Stem Tumors or Incompletely Resected Supratentorial Malignant Gliomas With Phase II Limited to Brain Stem Tumors Completed NCT00042991 Phase 1, Phase 2 gefitinib
42 Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms Completed NCT00004688 Phase 2 carmustine;mercaptopurine;streptozocin
43 A Pharmacokinetic and Phase 2 Study of Sunitinib Malate in Recurrent Malignant Gliomas Completed NCT00499473 Phase 2 sunitinib malate
44 Efficacy of a Protracted Temozolomide Schedule in Patients With Progression After Standard Dose Temozolomide for High-grade Gliomas Completed NCT00575887 Phase 2 Temozolomide
45 Cilengitide (EMD 121974) (IND# 59073) in Recurrent or Progressive and Refractory Childhood High-Grade Glioma Completed NCT00679354 Phase 2 cilengitide
46 A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas Completed NCT00995007 Phase 2 ZD6474 (Vandetanib);Carboplatin
47 A Phase 2 Trial of Tandutinib in Combination With Bevacizumab for Patients With Recurrent High-Grade Gliomas Completed NCT00667394 Phase 2 MLN-518 (Tandutinib)
48 Phase II Trial of Triple Receptor Tyrosine Kinase Receptor Inhibitor BIBF 1120 in Recurrent High-Grade Gliomas Completed NCT01380782 Phase 2 BIBF 1120
49 Proton Radiation for Low Grade Gliomas Completed NCT01024907 Phase 1, Phase 2
50 A Phase II Study of Bendamustine in the Treatment of Recurrent High-Grade Gliomas (Anaplastic Gliomas and Glioblastoma) Completed NCT00823797 Phase 2 Bendamustine Hydrochloride

Search NIH Clinical Center for Oligodendroglioma

Cochrane evidence based reviews: oligodendroglioma

Genetic Tests for Oligodendroglioma

Genetic tests related to Oligodendroglioma:

# Genetic test Affiliating Genes
1 Oligodendroglioma 29

Anatomical Context for Oligodendroglioma

MalaCards organs/tissues related to Oligodendroglioma:

40
Brain, Spinal Cord, Eye, Bone, Endothelial, Bone Marrow, Temporal Lobe

Publications for Oligodendroglioma

Articles related to Oligodendroglioma:

(show top 50) (show all 2824)
# Title Authors PMID Year
1
Spontaneous canine gliomas: overexpression of EGFR, PDGFRalpha and IGFBP2 demonstrated by tissue microarray immunophenotyping. 54 61
19967449 2010
2
Cyclooxygenase-2 expression in astrocytes and microglia in human oligodendroglioma and astrocytoma. 61 54
20052522 2009
3
Assessment of 1p/19q status by fluorescence in situ hybridization assay: A comparative study in oligodendroglial, mixed oligoastrocytic and astrocytic tumors. 61 54
19934553 2009
4
[Loss of heterozygosity of chromosome 1p/19q and p53 protein expression in oligodendroglioma]. 61 54
19781190 2009
5
[Common mechanism underlying oligodendrocyte development and oligodendrogliomagenesis]. 61 54
19618851 2009
6
Magnetic resonance perfusion-weighted imaging defines angiogenic subtypes of oligodendroglioma according to 1p19q and EGFR status. 61 54
19357963 2009
7
Evidence-based adjuvant therapy for gliomas: current concepts and newer developments. 61 54
19346643 2009
8
p16 promoter methylation in the serum as a basis for the molecular diagnosis of gliomas. 54 61
19240607 2009
9
[Expression of myelin basic protein and glial fibrillary acidic protein genes in human glial brain tumors]. 54 61
19663312 2009
10
Oligodendrogliomas in relation to astrocytes differentiation. Clinicopathologic and immunohistochemical study. 54 61
18774492 2008
11
[Radiotherapy of adult glial tumors: new developments and perspectives]. 61 54
18565351 2008
12
Olig2 and CD99 are useful negative markers for the diagnosis of brain tumors. 54 61
18552083 2008
13
Carbonic anhydrase II in the endothelium of glial tumors: a potential target for therapy. 61 54
17435181 2007
14
Receptor-targeted quantum dots: fluorescent probes for brain tumor diagnosis. 61 54
17867825 2007
15
Clinical significance of ABCA2' a possible molecular marker for oligodendrogliomas. 54 61
17415208 2007
16
Chromosome 1p and 19q status and p53 and p16 expression patterns as prognostic indicators of oligodendroglial tumors: a clinicopathological study using fluorescence in situ hybridization. 54 61
17319279 2007
17
Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas: use of YKL-40, ApoE, ASCL1, and NKX2-2. 54 61
17146289 2006
18
Expression of glutathione S-transferase T1 (GSTT1) in human brain tumours. 54 61
16874663 2006
19
Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. 61 54
16541434 2006
20
Survival analysis of presumptive prognostic markers among oligodendrogliomas. 61 54
16116609 2005
21
Correlation of glial fibrillary acidic protein (GFAP) with grading of the neuroglial tumours. 61 54
16202357 2005
22
OLIG2 (BHLHB1), a bHLH transcription factor, contributes to leukemogenesis in concert with LMO1. 54 61
16103065 2005
23
Ceramide regulation of the tumor suppressor phosphatase PTEN in rafts isolated from neurotumor cell lines. 61 54
15968641 2005
24
Oligodendrogliomas lacking O6-methylguanine-DNA-methyltransferase expression. 61 54
16038527 2005
25
Polymorphisms in GLTSCR1 and ERCC2 are associated with the development of oligodendrogliomas. 54 61
15834925 2005
26
Real-time quantitative PCR analysis of gene dosages reveals gene amplification in low-grade oligodendrogliomas. 61 54
15899783 2005
27
Mutational study of the 1p located genes p18ink4c, Patched-2, RIZ1 and KIF1B in oligodendrogliomas. 54 61
15711769 2005
28
Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. 54 61
15455350 2005
29
Gene expression profiling and subgroup identification of oligodendrogliomas. 61 54
15208679 2004
30
Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. 54 61
15118874 2004
31
p53 protein alterations in adult astrocytic tumors and oligodendrogliomas. 54 61
15269478 2004
32
Acid sphingomyelinase and inhibition by phosphate ion: role of inhibition by phosphatidyl-myo-inositol 3,4,5-triphosphate in oligodendrocyte cell signaling. 61 54
15086520 2004
33
Transcriptional regulation of the human UDP-galactose:ceramide galactosyltransferase (hCGT) gene expression: functional role of GC-box and CRE. 54 61
15229398 2004
34
Heterogeneity in the expression of markers for drug resistance in brain tumors. 61 54
14986930 2004
35
Tumour necrosis and microvascular proliferation are associated with 9p deletion and CDKN2A alterations in 1p/19q-deleted oligodendrogliomas. 61 54
14507338 2003
36
Expression of cyclins, cyclin-dependent kinases and cyclin-dependent kinase inhibitors in oligodendrogliomas in humans. 54 61
12873740 2003
37
Genetic determinants of malignancy in a mouse model for oligodendroglioma. 61 54
12670909 2003
38
CpG island methylation status and mutation analysis of the RB1 gene essential promoter region and protein-binding pocket domain in nervous system tumours. 54 61
12556968 2003
39
Genetic differences between neurocytoma and dysembryoplastic neuroepithelial tumor and oligodendroglial tumors. 61 54
12507133 2002
40
Galectin-3 labeling correlates positively in tumor cells and negatively in endothelial cells with malignancy and poor prognosis in oligodendroglioma patients. 54 61
12168841 2002
41
Suppression of Rac activity induces apoptosis of human glioma cells but not normal human astrocytes. 61 54
11929835 2002
42
Immunohistochemical analysis of p18INK4C and p14ARF protein expression in 117 oligodendrogliomas: correlation with tumor grade and clinical outcome. 61 54
11800646 2002
43
Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors. 61 54
11801559 2002
44
Losses of chromosomal arms 1p and 19q in the diagnosis of oligodendroglioma. A study of paraffin-embedded sections. 61 54
11557779 2001
45
The prognostic significance of DNA topoisomerase II-alpha (Ki-S1), p21/Cip-1, and p27/Kip-1 protein immunoexpression in oligodendrogliomas. 61 54
11419973 2001
46
Mutation analysis of the p73 gene in nonastrocytic brain tumours. 54 61
11461077 2001
47
Constitutive expression of growth-related oncogene and its receptor in oligodendrogliomas. 61 54
11322447 2001
48
Promoter hypermethylation and homozygous deletion of the p14ARF and p16INK4a genes in oligodendrogliomas. 54 61
11307615 2001
49
Analysis of 2 antiapoptotic factors in gliomas: bcl-2 overexpression and p53 mutations. 61 54
11175638 2001
50
Acetylcholinesterase and butyrylcholinesterase histochemical activities and tumor cell growth in several brain tumors. 61 54
11301094 2001

Variations for Oligodendroglioma

ClinVar genetic disease variations for Oligodendroglioma:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 CIC NM_015125.4(CIC):c.290_291insT (p.Gly99fs) Insertion Likely pathogenic 635171 rs1568503055 GRCh37: 19:42791230-42791231
GRCh38: 19:42287078-42287079
2 ATRX NM_000489.5(ATRX):c.4213A>G (p.Arg1405Gly) SNV Uncertain significance 635172 rs1569535987 GRCh37: X:76912051-76912051
GRCh38: X:77656561-77656561
3 IDH1 NM_001282386.1(IDH1):c.395G>A (p.Arg132His) SNV not provided 156444 rs121913500 GRCh37: 2:209113112-209113112
GRCh38: 2:208248388-208248388

Cosmic variations for Oligodendroglioma:

9 (show top 50) (show all 19848)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM88263021 ZRSR2 central nervous system,brain,glioma,anaplastic c.260G>A p.R87K 23:15803744-15803744 4
2 COSM88262556 ZRSR2 central nervous system,brain,glioma,oligodendroglioma c.220G>A p.E74K 23:15803704-15803704 4
3 COSM102048054 ZFHX3 central nervous system,brain,glioma,oligodendroglioma c.-23-6501G>A p.? 16:72957466-72957466 4
4 COSM149299313 ZFHX3 central nervous system,brain,glioma,anaplastic c.145C>T p.P49S 16:72960001-72960001 4
5 COSM149332069 ZFHX3 central nervous system,brain,glioma,oligodendroglioma c.2680G>A p.D894N 16:72957466-72957466 4
6 COSM87281264 ZFHX3 central nervous system,brain,glioma,oligodendroglioma c.3986G>A p.G1329E 16:72798696-72798696 4
7 COSM149332063 ZFHX3 central nervous system,brain,glioma,oligodendroglioma c.9154G>A p.V3052I 16:72793528-72793528 4
8 COSM149268215 ZFHX3 central nervous system,brain,glioma,oligodendroglioma c.6025T>C p.Y2009H 16:72796657-72796657 4
9 COSM102034961 ZFHX3 central nervous system,brain,glioma,anaplastic c.-23-9036C>T p.? 16:72960001-72960001 4
10 COSM102019608 ZFHX3 central nervous system,brain,glioma,anaplastic c.5905A>G p.M1969V 16:72794035-72794035 4
11 COSM149261414 ZFHX3 central nervous system,brain,glioma,oligodendroglioma c.8300G>A p.G2767E 16:72794382-72794382 4
12 COSM149260463 ZFHX3 central nervous system,brain,glioma,anaplastic c.8647A>G p.M2883V 16:72794035-72794035 4
13 COSM149318917 ZFHX3 central nervous system,brain,glioma,oligodendroglioma c.8600C>T p.S2867F 16:72794082-72794082 4
14 COSM102020229 ZFHX3 central nervous system,brain,glioma,oligodendroglioma c.5558G>A p.G1853E 16:72794382-72794382 4
15 COSM87291808 ZFHX3 central nervous system,brain,glioma,oligodendroglioma c.8600C>T p.S2867F 16:72794082-72794082 4
16 COSM87274123 ZFHX3 central nervous system,brain,glioma,oligodendroglioma c.6025T>C p.Y2009H 16:72796657-72796657 4
17 COSM102031113 ZFHX3 central nervous system,brain,glioma,oligodendroglioma c.1244G>A p.G415E 16:72798696-72798696 4
18 COSM87296761 ZFHX3 central nervous system,brain,glioma,oligodendroglioma c.9154G>A p.V3052I 16:72793528-72793528 4
19 COSM87271162 ZFHX3 central nervous system,brain,glioma,oligodendroglioma c.8300G>A p.G2767E 16:72794382-72794382 4
20 COSM102048046 ZFHX3 central nervous system,brain,glioma,oligodendroglioma c.6412G>A p.V2138I 16:72793528-72793528 4
21 COSM102022940 ZFHX3 central nervous system,brain,glioma,oligodendroglioma c.3283T>C p.Y1095H 16:72796657-72796657 4
22 COSM87284577 ZFHX3 central nervous system,brain,glioma,anaplastic c.145C>T p.P49S 16:72960001-72960001 4
23 COSM102042415 ZFHX3 central nervous system,brain,glioma,oligodendroglioma c.5858C>T p.S1953F 16:72794082-72794082 4
24 COSM87270740 ZFHX3 central nervous system,brain,glioma,anaplastic c.8647A>G p.M2883V 16:72794035-72794035 4
25 COSM149290610 ZFHX3 central nervous system,brain,glioma,oligodendroglioma c.3986G>A p.G1329E 16:72798696-72798696 4
26 COSM87296765 ZFHX3 central nervous system,brain,glioma,oligodendroglioma c.2680G>A p.D894N 16:72957466-72957466 4
27 COSM89896611 YES1 central nervous system,brain,glioma,oligodendroglioma c.259G>C p.A87P 18:756569-756569 4
28 COSM152022282 YES1 central nervous system,brain,glioma,oligodendroglioma c.259G>C p.A87P 18:756569-756569 4
29 COSM136838141 YES1 central nervous system,brain,glioma,oligodendroglioma c.274G>C p.A92P 18:756569-756569 4
30 COSM128446658 YAP1 central nervous system,brain,glioma,oligodendroglioma c.870+3470G>A p.? 11:102209544-102209544 4
31 COSM133267069 YAP1 central nervous system,brain,glioma,oligodendroglioma c.996+3458G>A p.? 11:102209544-102209544 4
32 COSM127992965 YAP1 central nervous system,brain,glioma,oligodendroglioma c.984+3470G>A p.? 11:102209544-102209544 4
33 COSM145022716 YAP1 central nervous system,brain,glioma,oligodendroglioma c.882+3458G>A p.? 11:102209544-102209544 4
34 COSM90942496 YAP1 central nervous system,brain,glioma,oligodendroglioma c.910G>A p.A304T 11:102209544-102209544 4
35 COSM143036045 YAP1 central nervous system,brain,glioma,oligodendroglioma c.1024G>A p.A342T 11:102209544-102209544 4
36 COSM126967812 YAP1 central nervous system,brain,glioma,oligodendroglioma c.478G>A p.A160T 11:102209544-102209544 4
37 COSM85231459 YAP1 central nervous system,brain,glioma,oligodendroglioma c.1012G>A p.A338T 11:102209544-102209544 4
38 COSM108084928 XIAP central nervous system,brain,glioma,anaplastic c.1057-2A>T p.? 23:123892729-123892729 4
39 COSM94291565 XIAP central nervous system,brain,glioma,anaplastic c.1057-2A>T p.? 23:123892729-123892729 4
40 COSM92181813 XIAP central nervous system,brain,glioma,anaplastic c.1057-2A>T p.? 23:123892729-123892729 4
41 COSM91365167 WT1 central nervous system,brain,glioma,oligodendroglioma c.7G>A p.D3N 11:32435339-32435339 4
42 COSM149722178 WT1 central nervous system,brain,glioma,oligodendroglioma c.7G>A p.D3N 11:32435339-32435339 4
43 COSM113469545 WT1 central nervous system,brain,glioma,oligodendroglioma c.7G>A p.D3N 11:32435339-32435339 4
44 COSM148571772 WT1 central nervous system,brain,glioma,oligodendroglioma c.7G>A p.D3N 11:32435339-32435339 4
45 COSM111523676 WT1 central nervous system,brain,glioma,oligodendroglioma c.7G>A p.D3N 11:32435339-32435339 4
46 COSM147406409 WT1 central nervous system,brain,glioma,oligodendroglioma c.7G>A p.D3N 11:32435339-32435339 4
47 COSM95872527 VTCN1 central nervous system,brain,glioma,anaplastic c.413C>T p.S138F 1:117156615-117156615 4
48 COSM91946697 VTCN1 central nervous system,brain,glioma,anaplastic c.98-3246C>T p.? 1:117156615-117156615 4
49 COSM96870342 VTCN1 central nervous system,brain,glioma,anaplastic c.404C>T p.S135F 1:117156615-117156615 4
50 COSM108959161 VTCN1 central nervous system,brain,glioma,anaplastic c.*228C>T p.? 1:117156615-117156615 4

Copy number variations for Oligodendroglioma from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13342 1 1 124300000 Loss Oligodendroglial tumors
2 42816 10 40300000 135374737 Loss Oligodendroglial tumors
3 119741 18 16100000 76117153 Loss Oligodendroglial tumors
4 124095 19 1 28500000 Gain Oligodendroglial tumors
5 127178 19 28500000 63811651 Loss Oligodendroglial tumors
6 187538 4 50700000 191273063 Loss Oligodendroglial tumors
7 217108 7 1 59100000 Gain Oligodendroglial tumors
8 226562 7 59100000 158821424 Gain Oligodendroglial tumors
9 244959 9 1 51800000 Loss Oligodendroglial tumors

Expression for Oligodendroglioma

Search GEO for disease gene expression data for Oligodendroglioma.

Pathways for Oligodendroglioma

Pathways related to Oligodendroglioma according to GeneCards Suite gene sharing:

(show all 24)
# Super pathways Score Top Affiliating Genes
1 12.73 TP53 PTEN EGFR CDKN2B CDKN2A
2
Show member pathways
12.63 TP53 PTEN EGFR CDKN2B CDKN2A
3
Show member pathways
12.45 TP53 PTEN EGFR CDKN2C CDKN2B CDKN2A
4
Show member pathways
12.27 TP73 TP53 PTEN CDKN2A
5 12.25 TP53 CDKN2C CDKN2B CDKN2A
6
Show member pathways
12.23 TP53 CDKN2C CDKN2B CDKN2A
7 12.21 TP73 TP53 MGMT GMNN CDKN2C CDKN2A
8 12.14 TP53 PTEN CDKN2C CDKN2B CDKN2A
9 12.02 TP53 PTEN CDKN2B CDKN2A
10 11.93 TP73 TP53 PTEN EGFR
11 11.87 TP53 MBP GFAP EGFR
12 11.84 TP73 TP53 PTEN CDKN2A
13 11.77 OLIG2 OLIG1 MBP GFAP
14 11.76 TP53 PTEN CDKN2B
15 11.62 TP53 EGFR CDKN2A
16 11.6 TP53 PTEN MGMT EGFR CDKN2A
17 11.55 TP53 PTEN ATRX
18 11.52 SYP OLIG2 OLIG1 GFAP
19 11.43 TP53 EGFR CDKN2A
20 11.38 TP53 PTEN CDKN2B
21
Show member pathways
10.95 TP73 TP53 CDKN2A
22 10.87 TP53 PTEN IDH2 IDH1 EGFR
23 10.76 TP53 CDKN2C CDKN2B CDKN2A
24
Show member pathways
10.73 IDH2 IDH1

GO Terms for Oligodendroglioma

Cellular components related to Oligodendroglioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.53 TP73 TP53 PTEN POT1 OLIG2 OLIG1

Biological processes related to Oligodendroglioma according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 cell cycle GO:0007049 9.95 TP73 TP53 GMNN CDKN2C CDKN2B CDKN2A
2 negative regulation of cell proliferation GO:0008285 9.8 TP73 TP53 PTEN CDKN2C CDKN2B CDKN2A
3 response to organic cyclic compound GO:0014070 9.76 PTEN MGMT IDH1 EGFR
4 positive regulation of cell cycle arrest GO:0071158 9.61 TP73 TP53 CDKN2A
5 oligodendrocyte differentiation GO:0048709 9.58 OLIG2 OLIG1 CDKN2C
6 negative regulation of telomerase activity GO:0051974 9.54 TP53 POT1
7 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.52 TP53 EGFR
8 NADP metabolic process GO:0006739 9.51 IDH2 IDH1
9 isocitrate metabolic process GO:0006102 9.49 IDH2 IDH1
10 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.46 PTEN CDKN2C CDKN2B CDKN2A
11 negative regulation of phosphorylation GO:0042326 9.43 CDKN2C CDKN2B CDKN2A
12 glyoxylate cycle GO:0006097 9.37 IDH2 IDH1
13 cell cycle arrest GO:0007050 9.35 TP73 TP53 CDKN2C CDKN2B CDKN2A
14 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 8.92 PTEN CDKN2C CDKN2B CDKN2A

Molecular functions related to Oligodendroglioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA binding GO:0003677 10.07 TP73 TP53 POT1 OLIG2 OLIG1 MGMT
2 identical protein binding GO:0042802 10.01 TP73 TP53 SYP PTEN OLIG2 IDH1
3 chromatin binding GO:0003682 9.85 TP53 GMNN EGFR CIC ATRX
4 p53 binding GO:0002039 9.61 TP73 TP53 CDKN2A
5 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.33 CDKN2C CDKN2B CDKN2A
6 isocitrate dehydrogenase (NADP+) activity GO:0004450 9.32 IDH2 IDH1
7 isocitrate dehydrogenase activity GO:0004448 9.26 IDH2 IDH1
8 protein kinase binding GO:0019901 9.17 TP73 TP53 PTEN EGFR CDKN2C CDKN2B
9 MDM2/MDM4 family protein binding GO:0097371 9.13 TP73 TP53 CDKN2A

Sources for Oligodendroglioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....